Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

2.

Early Tislelizumab May Boost PFS in Esophageal Cancer

3.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

How to keep your prostate healthy and lower your risk of developing serious problems


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot